OvaScience’s AUGMENT Takes A Pregnant Pause In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech voluntarily suspended a U.S. trial of its IVF-enhancing cell therapy after receiving word from FDA that it needs to follow a different regulatory path.
You may also be interested in...
Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public
Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.